ACP
IMA

Acuta Capital Partners’s ImageneBio Inc IMA Stock Holding History

Acuta Capital Partners’s Portfolio IMA Stock Details IMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-45,918
Closed -$2.39M – 48
2023
Q3 		$2.39M Sell
45,918
-582
-1% -$35K 1.6% 23
2023
Q2 		$3.66M Buy
+46,500
New +$3.33M 2.48% 17

Other funds holding IMA

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Acuta Capital Partners's IMA Position: Q4 2023 in Review

Acuta Capital Partners sold out of ImageneBio Inc (IMA) in Q4 2023, closing a stake of 45,918 shares — an estimated $2.39M sold.

Acuta Capital Partners first reported a position in IMA in Q2 2023 and held it in 2 quarters. The position peaked at $3.66M in Q2 2023. 54 funds tracked by Wall St. Rank hold IMA as of Q4 2023.

  • Acuta Capital Partners reported no remaining ImageneBio Inc position as of Q4 2023 after selling out during the quarter.
  • Acuta Capital Partners sold 45,918 ImageneBio Inc shares in Q4 2023, an estimated $2.39M.
  • Acuta Capital Partners first reported a position in ImageneBio Inc in Q2 2023 and held it in 2 quarters.
  • Acuta Capital Partners's ImageneBio Inc position peaked at $3.66M in Q2 2023.
  • 54 funds tracked by Wall St. Rank held ImageneBio Inc as of Q4 2023.

Based on Acuta Capital Partners's 13F filing for Q4 2023, filed 14 Feb 2024.